Insider · CIK 0001557832
Cam Gallagher
Files at IRD (Opus Genetics, Inc.). First filing Dec 31, 2025, latest Dec 31, 2025.
Cam Gallagher files SEC Form 4 as director at IRD (Opus Genetics, Inc.). Since Dec 31, 2025, Cam Gallagher has reported 1 open-market buy worth $324k and 0 open-market sells worth $0, the latest filed on Dec 31, 2025.
A track record needs three past buys with six months of prices behind them; Cam Gallagher has 0, so none is measured yet.
The newest scored trade: bought $324k of IRD on Dec 29, 2025, filed Dec 31, 2025, scored 36 (weak). In the last 12 months: 1 buy worth $324k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IRD: Opus Genetics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | IRDbuy Opus Genetics, Inc. | $324k 164,000 shares | +9% | +180% from low-20% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 11, 2025 | ZNTL Zentalis Pharmaceuticals, Inc. | 687 0.00% of outstanding | $1,374 | Feb 11, 2025 | $49k |
| Feb 3, 2025 | ZNTL Zentalis Pharmaceuticals, Inc. | 28,558 0.04% of outstanding | $49k | Feb 3, 2025 | none |
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | IRD Opus Genetics, Inc. | MOption exercise Common Stock | +784,314 | $1.15 | $902k | 2,800,111 | 35 d ago |
| Sep 8, 2026 | IRD Opus Genetics, Inc. | MOption exercise Warrant (right to buy)derivative | -784,314 | $0.00 | $0 | 0 | 35 d ago |
| Apr 20, 2026 | IRD Opus Genetics, Inc. | AGrant or award Common Stock | +24,367 | $0.00 | $0 | 2,015,797 | Apr 22, 2026 |
| Jan 6, 2026 | IRD Opus Genetics, Inc. | AGrant or award Common Stock | +67,000 | $0.00 | $0 | 1,991,430 | Jan 8, 2026 |
| Dec 29, 2025 | IRD Opus Genetics, Inc. | POpen-market purchase Common Stock | +81,000 | $1.98 | $160k | 1,891,430 | Dec 31, 2025 |
| Dec 29, 2025 | IRD Opus Genetics, Inc. | POpen-market purchase Common Stockindirect: By Garret Gallagher - Custodian UTMA/UGMA | +83,000 | $1.97 | $163k | 83,000 | Dec 31, 2025 |
| Dec 31, 2025 | IRD Opus Genetics, Inc. | AGrant or award Common Stock | +33,000 | $0.00 | $0 | 1,924,430 | Dec 31, 2025 |
| Aug 25, 2025 | IRD Opus Genetics, Inc. | AGrant or award Common Stock | +869,565 | $1.15 | $1000k | 1,810,430 | Aug 27, 2025 |
| Apr 30, 2025 | IRD Opus Genetics, Inc. | AGrant or award Common Stock | +79,504 | $0.00 | $0 | 940,865 | May 2, 2025 |
| Apr 30, 2025 | IRD Opus Genetics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +79,592 | $0.00 | $0 | 79,592 | May 2, 2025 |
| Mar 24, 2025 | IRD Opus Genetics, Inc. | AGrant or award Common Stock | +784,314 | - | - | 861,361 | Mar 26, 2025 |
| Mar 24, 2025 | IRD Opus Genetics, Inc. | AGrant or award Warrants (right to buy)derivative | +784,314 | - | - | 784,314 | Mar 26, 2025 |
Questions about Cam Gallagher
Answered from the filings on this page, as of the latest one.
Is Cam Gallagher buying or selling?
In the last 12 months Cam Gallagher reported 1 open-market buy worth $324k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $324k of IRD on Dec 29, 2025. Grants, option exercises and tax withholding are not counted.
How did Cam Gallagher's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Cam Gallagher has 0.
Where does Cam Gallagher file Form 4?
Cam Gallagher has filed Form 4 at IRD (Opus Genetics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.